A prospective controlled trial was performed to determine whether the use of ABO-identical platelets from the start of treatment might provide higher post-transfusion platelet increments, reduce the number of platelet transfusions and ultimately delay the onset of refractoriness. Forty newly diagnosed patients with haematological diseases were randomized to receive either pooled ABO-identical platelets or pooled platelets unmatched for ABO group throughout their course. The corrected platelet count increments (CCI) were calculated for the first 25 transfusions of each patient and non-immune factors present at the time of each platelet transfusion were documented. The mean CCI for the first 25 transfusions in the ABO-identical group was significantly higher (6600 +/- 7900 SD) than that achieved with ABO unmatched platelets (5200 +/- 7900; p < 0.01). The effect was most marked for the first 10 transfusions for each patient where the CCI was 64% higher in the ABO-identical group (8200 +/- 7500 vs 5000 +/- 8100; p < 0.0002). Patients given ABO-identical platelets required only about half as many transfusions in the first 30 days (10 versus 17, p < 0.05) or during the first admission (11 versus 21 p < 0.01) as patients in the ABO-unmatched group. A smaller percentage of patients in the ABO-identical group became refractory (36% vs 75% p < 0.03). The data suggest that patients requiring long-term platelet support should be transfused with ABO-identical platelets.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0609.1993.tb00150.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate.
Transfusion
January 2025
Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Article Synopsis
- This study investigates the balance between avoiding platelet wastage and ensuring transfusion efficacy, focusing on the effects of platelet compatibility and product modification on reaction rates.
- A review of over 21,000 platelet transfusions revealed a 1.33% reaction rate, with major incompatibility and irradiated products associated with increased odds of adverse reactions.
- The findings suggest that both platelet compatibility and product modification independently impact transfusion reactions, informing future policies for selecting platelet products for patients.
Purified Granulocyte Concentrates from Buffy Coats with Extended Storage Time.
Transfus Med Hemother
December 2024
Artcline GmbH, Rostock, Germany.
Article Synopsis
- Granulocyte concentrates (GCs) can be made from pooled buffy coats of whole blood donations, allowing for better availability and longer storage times compared to those made from single-donor apheresis, which can only last 24 hours.
- A process was developed to significantly reduce red blood cell and platelet contamination, extending the shelf life of GCs up to 72 hours while maintaining high cell viability (above 98%) and functionality (with over 95% rates of phagocytosis and oxidative burst).
- To produce a therapeutic dose of GCs, around 15-20 buffy coats are needed, offering a more efficient alternative for treatment compared to traditional methods.
ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage.
PLoS One
November 2024
Department of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia, United States of America.
Article Synopsis
- The study investigates the effects of ABO compatibility on platelet transfusion outcomes in patients with spontaneous and traumatic intracranial hemorrhage (ICH).
- It hypothesizes that ABO-identical transfusions would result in better post-transfusion platelet increments and improved neurologic outcomes compared to incompatible transfusions.
- Results show no significant differences in platelet increments or clinical outcomes among patients receiving ABO-identical, major incompatible, or minor incompatible transfusions, suggesting ABO compatibility may not be as crucial as previously thought.
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.
Blood Adv
September 2024
Division of Hematology/Oncology, University of Washington, Seattle, WA.
Article Synopsis
- Up to one-third of patients with blood cancers who have received multiple transfusions develop immune-mediated issues that make platelet transfusions less effective, known as platelet transfusion refractoriness.
- This study analyzed 2012 platelet transfusions in 73 patients to examine how HLA antibodies and other patient factors influence the effectiveness of these transfusions, specifically looking at their impact on the corrected count increment (CCI) after 2 and 24 hours.
- Results showed that high levels of donor-specific antibodies, certain blood type mismatches, and other specific conditions negatively affected immediate posttransfusion platelet counts, suggesting that using a computerized algorithm for donor-recipient matching could improve outcomes in these patients.
Delayed cold-stored vs. room temperature stored platelet transfusions in bleeding adult cardiac surgery patients-a randomized multicentre pilot study (PLTS-1).
Pilot Feasibility Stud
June 2024
Department of Anesthesia and Pain Management, Sinai Health System, Women's College Hospital, University Health Network, Toronto, ON, Canada.
Article Synopsis
- The study investigates the potential benefits of Delayed Cold-Stored Platelets (DCSP) over standard Room Temperature Platelets (RTP) for improving the effectiveness and lifespan of platelets used in cardiac surgeries.
- The trial involves 50 adult patients scheduled for complex cardiac surgery, who will be randomly assigned to receive either RTP or DCSP, with the intervention lasting from the end of surgery to 24 hours afterward.
- The main goals are to assess the feasibility of a larger randomized controlled trial (RCT) and evaluate the safety and effectiveness of DCSP compared to RTP in reducing the total amount of blood products needed after surgery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!